Item 9 Labs Corp
OTC:INLB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (0), the stock would be worth $0 (0% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0 | $0 |
0%
|
| 3-Year Average | 0 | $0 |
0%
|
| 5-Year Average | 0 | $0.03 |
+26 600%
|
| Industry Average | 3.8 | $37.69 |
+37 688 900%
|
| Country Average | 2.5 | $25.14 |
+25 137 300%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Item 9 Labs Corp
OTC:INLB
|
701.8 USD | 0 | -0 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 31.1 | 40 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 6.7 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 5.9 | 27.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.9B CHF | 6 | 19.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 5.2 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 6.1 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 1.7 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 6.3 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Item 9 Labs Corp
Glance View
Item 9 Labs Corp. is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The company is headquartered in Phoenix, Arizona and currently employs 103 full-time employees. The company went IPO on 2011-11-03. The firm produces cannabis and cannabis-related products and offers approximately 75 active cannabis strains and more than 150 differentiated cannabis vape products as well as premium concentrates and Orion vape technologies. The firm's Item 9 Labs brand specializes in select products and user experience across several cannabis categories. The firm also offers a dispensary franchise model through the national Unity Rd. retail brand. Item 9 Labs cultivates elevated mainstream cannabis flower, vape cartridges, concentrates and Apollo & Orion vape technologies. The Company’s products are available to consumers through licensed dispensaries in Arizona. Its products are carried in more than 70 dispensaries throughout the state of Arizona.
